

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	4 FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	5 FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	6 FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	7 FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	8 MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	9 MAR 22	EMBASE is now updated on a daily basis
NEWS	10 APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	11 APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	12 APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	13 APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	14 APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	15 APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS	16 MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	17 MAY 11	KOREAPAT updates resume
NEWS	18 MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	19 MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	20 MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	21 JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS EXPRESS	FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability	
NEWS LOGIN	Welcome Banner and News Items	
NEWS IPC8	For general information regarding STN implementation of IPC 8	
NEWS X25	X.25 communication option no longer available after June 2006	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:09:41 ON 26 JUN 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:09:46 ON 26 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUN 2006 HIGHEST RN 889359-45-9

DICTIONARY FILE UPDATES: 25 JUN 2006 HIGHEST RN 889359-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10781442amend.str



chain nodes :

6 7 8 9 11 12 14 16

ring nodes :

1 2 3 4 5

chain bonds :

4-6 5-12 6-7 6-9 7-8 7-11 12-14 14-16

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-6 5-12 6-7 6-9 7-8 7-11 12-14 14-16

isolated ring systems :

containing 1 :

G1:H,Ak

G2:N,SO2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:Atom 9:CLASS 11:CLASS
12:CLASS 14:CLASS 16:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak
G2 N,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:10:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1645 TO ITERATE

100.0% PROCESSED 1645 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 30467 TO 35333
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:10:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 33156 TO ITERATE

100.0% PROCESSED 33156 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.02

L3 10 SEA SSS FUL L1

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'HCAPLUS' ENTERED AT 09:10:39 ON 26 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Jun 2006 VOL 145 ISS 1
FILE LAST UPDATED: 25 Jun 2006 (20060625/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.



This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s 13

L4 14 L3

=> d ed abs ibib hitstr 1-14

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 04 Mar 2005
 GI



AB The invention relates to a preparation of urotensin II receptor antagonists and CCR-9 antagonists of formula I (wherein: R1, R2, and R3 are independently selected from H, halogen, alkyl, aryl, or CN, etc.; X is CH2, O, or NH, etc.; Y is SO2, C(O), CH2SO2, NHC(O), or NHC(S), etc.; T and V are independently selected from H, (cyclo)alkyl, alkoxy, aryl, or halogen, etc.; R4 is aryl, heterocyclyl, or cycloalkyl). For instance, thienophenecarboxamide derivative II was prepared via amidation of thiophene-2-carboxylic acid by 2,4,6-trimethyl-3-(pyrrolidin-1-yl)phenylamine. The invention compds. were tested for inhibition of human urotensin II-induced Ca²⁺ mobilization in UTR cells (IC50 > 0.5 μM).

ACCESSION NUMBER: 2005:185392 HCAPLUS
 DOCUMENT NUMBER: 142:280229
 TITLE: A preparation of urotensin II receptor antagonists and CCR-9 antagonists
 INVENTOR(S): Wu, Chengde; Anderson, C. Eric; Bui, Huong; Gao, Dexin; Kassir, Jamal; Li, Wen; Wang, Junmei; Biediger, Ronald; Chen, Jie; Market, Robert V.
 PATENT ASSIGNEE(S): USK
 SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 781,442.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----


L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 14 Dec 2004

AB Two extensive studies quantifying the ability of topomer shape similarity to forecast a variety of biol. similarities are described. In a prospective trial of "lead hopping", using topomer similarity for virtual screening and queries from the patent literature, biol. assays of 308 selected compds. (representing 0.03% of those available, per assay type) yielded 11 successful "lead hops" in the 13 assays attempted. The hit rate averaged over all assays was 39% ("activity" defined as inhibition ≥20% at 10 μM), significantly greater than an unexpectedly high neg. control hit rate of 15%. The average "Tanimoto 2D fingerprint similarity" between query and "lead hop" structures (0.36) was little more than the Tanimoto similarity between random drug-like structures. Topomer shape and Tanimoto 2D fingerprint similarities were also compared retrospectively, in their tendencies to concentrate together potential and actual drugs reported to belong to the same "activity class", for twenty classes. Among the most similar 3% of structures (corresponding to "≥0.85 Tanimoto" for these structures), an average of 62% of the topomer similar selection possessed a near neighbor belonging to the same activity class, roughly a one-third superiority over the "Tanimoto ≥ 0.85" selection containing 48% actives in avoiding false positives. Conversely, the least similar 75% of structures contained 0.3% actives for topomer similarity vs. 1.0% actives for Tanimoto 2D fingerprint similarity, a 3-fold superiority for topomers in avoiding false negatives.


ACCESSION NUMBER: 2004:1068075 HCAPLUS
 DOCUMENT NUMBER: 142:168975
 TITLE: "Lead Hopping". Validation of Topomer Similarity as a Superior Predictor of Similar Biological Activities
 AUTHOR(S): Cramer, Richard D.; Jilek, Robert J.; Gueszregan, Stefan; Clark, Stephanie J.; Wendt, Bernd; Clark, Robert D.
 CORPORATE SOURCE: Tripos Discovery Research, Cornwall, EX23 8LY, UK
 SOURCE: Journal of Medicinal Chemistry (2004), 47(27), 6777-6791
 CODEN: JMCHAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 832131-75-6, DR 9704611
 RL: PAC (Pharmacological activity); BIOL (Biological study) (validation of topomer similarity as a superior predictor of similar biol. activities of "Lead hopping")
 RN 832131-75-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-N-(2-cyano-4,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 US 2005049286 A1 20050303 US 2004-924180 20040823
 US 2004180892 A1 20040916 US 2004-781442 20040218
 PRIORITY APPLN. INFO.: US 2003-448791P 20030220
 US 2004-781442 A2 20040218


OTHER SOURCE(S): MARPAT 142:280229
 IT 847414-56-6P 847414-58-6P 847414-59-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of urotensin II receptor antagonists and CCR-9 antagonists)
 RN 847414-56-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-58-8 HCAPLUS
 CN 3-Thiophenecarboxamide, 4,5-dimethyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-59-9 HCAPLUS
 CN 3-Thiophenecarboxamide, 4-methyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Aug 2002
GI



AB The title sulfonamides Ar2-SO2-NH-Ar1 [1: Ar1 = (un)substituted 5-6 membered heteroaryl; Ar2 = thienyl, furyl, pyrrolyl] and their pharmaceutically acceptable salts, useful for modulating or altering the activity of the endothelin family of peptides, were prepared and formulated. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, are provided. A table of approx. 300 compds. 1, and over 30 detailed synthetic examples, are given. For instance, 5-methylbenzo[d][1,3]dioxole in CH2Cl2 reacted with HCl and formaldehyde in the presence of Bu4NBr to give 5-(chloromethyl)-6-methylbenzo[d][1,3]dioxole. Grignard reaction of this with N-methoxy-N-methyl-3-(4-chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thiophenecarboxamide gave title compound II, which was isolated as the free acid, dissolved in EtOAc, and treated with saturated aqueous NaHCO3, to give the sodium salt II.Na in 98.2% purity. Alternatively, treatment of II with an equimolar amount of Na2HPO4 in aqueous MeCN gave the salt II.H3PO4.2Na. A solution

of II.Na and USP dextrose in phosphate buffer was filtered into vials and lyophilized, to give injectable II.Na for use at 25 mg/mL or 12.5 mg/mL. The aforementioned salts both showed improved solubility and stability in various aqueous media, such as Labrasol, compared to the free acid II.

ACCESSION NUMBER: 2002:610408 HCAPLUS
DOCUMENT NUMBER: 137:154844
TITLE: Preparation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders
INVENTOR(S): Wu, Chengde; Blok, Natalie; Patricia, Woodard Timothy;
Kwiler, Karin; Woodard, Patricia
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 65 pp., Cont.-in-part of U.S. 6,248,767.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6432994	B1	20020813	US 2000-403599	20000327

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 17 Jul 2002
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Thienyl-, furyl-, and pyrrolylsulfonamides, formulations of pharmaceutically acceptable salts thereof, and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, disclosures include N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compds. are described by the formula Ar2SO2NHArl [1: wherein Ar1 = (un)substituted monocyclic or polycyclic heteroaryl, particularly isoxazolyl; Ar2 = G1 or G2; M = (CH2)mCO(CH2)n, (CH2)mCONH(CH2)n, (CH2)mCH(CH2)n, (CH2)mCO(CH2)pNH(CH2)n, C1N(OH)(CH2)n, (CH2)mCO(CH2)pNH(CH2)n, CH(OH)(CH2)n, CH(CH3)CO(CH2)n, CH(CH3)CO(CH2)mCH(CH2)n, (CH2)n, (CH2)nO, CH2SO2-2, or CO2; m, n, and p = independently 0-6; R1-R5 = independently H, OH, NO2, CN, halo, alkyl, alkenyl, alkynyl, (hetero)aryl, arylalkyl, alkylamino, alkythio, haloalkyl, alkory, alkylsulfonfyl, (un)substituted amino, carbamoyl, etc.; or 2 adjacent R1-R5 form alkylenedioxy, alkylenedithioxy, or alkylenedithioxy; with provisos: X = S, O, or NR11; R11 = H, (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, heterocyclyl, aralkyl, aralkoxy, alkylalkenyl, alkylalkynyl, OH, CN, acyl, acyloxy, carboxy, SH, NHOH, (un)substituted amino, carbamoyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of 1 or their prodrugs are also provided. Such disorders include hypertension, cardiovascular disease, asthma, hypertension, inflammatory disease, glaucoma, etc. Twenty synthetic examples are given, and numerous example compds. were prepared, tested, and/or claimed. For instance, 3-cyanomethyl-2,4,6-trimethylphenylamine was treated with H2SO4 in MeOH to give Me 3-amino-2,4,6-trimethylphenylacetate (881). Amidation with N-(4-chloro-3-methyl-5-isoxazolyl)-3-sulfamoylthiophene-2-carboxylic acid using 1,1'-carbonyldiimidazole in DMF afforded II (151). The similarly prepared title compound III exhibited IC50 values of 0.0015 ± 0.0014 µM for ETA receptors and 0.324 ± 0.78 µM for ETB receptors. Claimed compds. also exhibited improved oral half-life, bioavailability, and/or in vivo activity over those disclosed previously.

ACCESSION NUMBER: 2002:534073 HCAPLUS
DOCUMENT NUMBER: 137:93741
TITLE: Preparation of N-isoxazolyl aryl-substituted thienyl-, furyl-, and pyrrolylsulfonamides and derivatives as endothelin activity modulators
INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Blok, Natalie
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: U.S., 59 pp., Cont.-in-part of U. S. 5,962,490.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6420567	B1	20020716	US 1997-938325	19970926
US 5962490	A	19991005	US 1996-721183	19960927
AU 9935803	A1	19990916	AU 1999-35803	19990622
AU 726595	B2	20001116		

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 5783705 A 19980721 US 1997-847797 19970428
US 6248767 B1 20010619 US 1997-938444 19970926
WO 9849162 A1 19981105 WO 1998-US6680 19980402
V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZV
RW: GH, GM, KE, LS, MV, SD, SZ, UG, ZW, AT, BE, CH, CY, OE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, ML, MR, NE, SN, TD, TG
US 2002091270 A1 20020711 US 2001-29561 20011220
US 6683103 B2 20040127
PRIORITY APPLN. INFO.: US 1997-847797 A2 19970428
US 1997-938444 A2 19970926
WO 1998-US6680 W 19980402
US 2000-403599 A3 20000327


OTHER SOURCE(S): MARPAT 137:154844
IT 184035-85-6P, N-(3,4-Dimethyl-5-isoxazolyl)-3-(phenylamino)carbonylthiophene-2-sulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 271 THERE ARE 271 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 2002091272 A1 20020711 US 2001-11610 20011105
US 6632829 B2 20031014
US 2003208084 A1 20031106 US 2003-447763 20030528
PRIORITY APPLN. INFO.: US 1996-721183 A2 19960927
US 1987-100865 A2 19870925
US 1990-416199 A2 19900515
US 1993-65202 B2 19930520
US 1993-100125 B2 19930730
US 1993-100565 A2 19930730
US 1993-142159 A2 19931021
US 1993-142552 A2 19931021
US 1993-142631 B2 19931021
US 1994-222287 A2 19940405
US 1994-247072 A2 19940520
US 1995-417075 A2 19950404
US 1995-477223 A2 19950606
AU 1996-55367 A 19960404
WO 1996-US4759 A 19960404
US 1997-938325 A3 19970926
US 2001-11610 A3 20011105

OTHER SOURCE(S): MARPAT 137:93741
IT 184035-85-6P, N-(3,4-Dimethyl-5-isoxazolyl)-3-(phenylamino)carbonylthiophene-2-sulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(endothelin modulator; preparation of N-isoxazolyl aryl-substituted thienyl-, furyl-, and pyrrolylsulfonamides and derivs. as endothelin activity modulators)
RN 184035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 211 THERE ARE 211 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ED Entered STN: 12 Apr 2002
GI



AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alkyl interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared. E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

ACCESSION NUMBER: 2002:275753 HCAPLUS
DOCUMENT NUMBER: 136:309843
TITLE: Preparation of thiophenes as phosphate transport inhibitors
INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028353	A2	20020411	WO 2001-US31318	20011005
WO 2002028353	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ED Entered STN: 13 Jul 2001

AB Pharmaceutical and veterinary uses of endothelin antagonists are provided. In particular, methods of treatment of laminitis, such as equine and bovine laminitis, by administration of one or more endothelin antagonists are provided. Methods are also provided for the treatment, prevention, or amelioration of one or more symptoms of menopause; osteoporosis and metabolic bone disorders; climacteric disorders, including hot flashes or flashes, abnormal clotting patterns, urogenital discomfort and increased incidence of cardiovascular disease, and other disorders associated with the reduction in ovarian function in women; pre-eclampsia; and control and management of labor during pregnancy by administration of endothelin antagonists.


ACCESSION NUMBER: 2001:507533 HCAPLUS
DOCUMENT NUMBER: 135:102580
TITLE: Pharmaceutical and veterinary uses of endothelin antagonists for treatment of laminitis and other conditions, and preparation thereof
INVENTOR(S): Brock, Thomas A.; Ward, Patrick R.
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049289	A1	20010712	WO 2000-US35280	20001227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001024567 AU 2001-24567 20001227				
PRIORITY APPLN. INFO.: US 1999-174125P P 19991231				
WO 2000-US35280 W 20001227				


OTHER SOURCE(S): MARPAT 135:102580
IT 104035-85-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endothelin antagonists for veterinary or pharmaceutical use in treatment of laminitis and other conditions)
RN 104035-85-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RV: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG
AU 2002013048 AS 20020415 AU 2002-13048 20011005
PRIORITY APPLN. INFO.: US 2000-239068P P 20001005
WO 2001-US31318 W 20011005

OTHER SOURCE(S): MARPAT 136:309843
IT 409364-73-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenes as phosphate transport inhibitors)
RN 409364-73-4 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-2-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ED Entered STN: 21 Jun 2001
 GI




AB Formulations of pharmaceutically acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations, are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor, by contacting the receptor with the sulfonamide salt, are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more of these sulfonamide salts or prodrugs thereof, that inhibit or increase the activity of endothelin, are also provided. In particular, pharmaceutically acceptable salts of compounds Ar2-SO2-NH-Ar1 [I; where Ar1 = 5-membered heteroaryl; Ar2 = thienyl or thionaphthyl; salt is with an alkali metal or mineral acid] are claimed. A table of approx. 300 compounds, I, and over 30 detailed synthetic examples, are given. For instance, 5-methylbenzo[d][1,3]dioxole in CH2Cl2 reacted with HCl and formaldehyde in the presence of Bu4NBr to give 5-(chloromethyl)-6-methylbenzo[d][1,3]dioxole. Grignard reaction of this with N-methoxy-N-methyl-3-(4-chloro-3-methyl-5-isoxazolylsulfamoyl)-2-thiophenecarboxamide gave title compound II, which was isolated as the free acid, dissolved in EtOAc, and treated with saturated aqueous NaHCO3, to give the sodium salt II.Na in 98.2% purity. Alternatively, treatment of II with an equimolar amount of Na2HPO4 in aqueous MeCN gave the salt II.H3PO4.2Na. A

solution of II.Na and USP dextrose in phosphate buffer was filtered into vials and lyophilized, to give injectable II.Na for use at 25 mg/mL or 12.5 mg/mL. The aforementioned salts both showed improved solubility and stability in various aqueous media, such as Labrasol, compared to the free acid II. ACCESSION NUMBER: 2001:449271 HCAPLUS DOCUMENT NUMBER: 135:46080 TITLE: Formulation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders INVENTOR(S): Blok, Natalia; Wu, Chengde; Woodward, Patricia; Keller, Karin; Kogan, Timothy PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA SOURCE: U.S., 58 pp., Cont.-in-part of U.S. 5,783,705.

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 US 2002091270 A1 20020711 US 2001-29561 20011220
 US 6683103 B2 20040127

PRIORITY APPLN. INFO.: US 1997-847797 A2 19970428
 US 1997-938444 A 19970926
 CA 1998-2281090 A3 19980402
 EE 1999-469 A 19980402
 EP 1998-915281 A3 19980402
 IL 1998-131318 A3 19980402
 JP 1998-540982 A3 19980402
 WO 1998-56680 W 19980402
 US 2000-403599 A3 20000327

OTHER SOURCE(S): MARPAT 135:46080
 IT 184035-85-6P, N-(3-(4-dimethyl-5-isoxazolyl))-3-(phenylaminocarbonyl)thiophene-2-sulfonamide
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation and formulation of heterocyclic sulfonamides for treatment of endothelin-mediated disorders)
 RN 184035-85-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 219 THERE ARE 219 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

DOCUMENT TYPE: CODEN: USXXAM
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6248767	B1	20010619	US 1997-938444	19970926
US 5783705	A	19980721	US 1997-847797	19970428
CA 2281090	AA	19981105	CA 1998-2281090	19980402
CA 2496680	A	20050607		
WO 9849162	A1	19981105	CA 1998-2496680	19980402
			WO 1998-056680	19980402
V: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MV, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, ML, MR, NE, SN, TD, TG				
AU 9869504	A1	19981124	AU 1998-69504	19980402
AU 749167	B2	20020620		
EP 980369	A1	20000223	EP 1998-915281	19980402
EP 980369	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900469	A	20000615	EE 1999-469	19980402
EE 4156	B1	20031015		
BR 9812258	A	20000725	BR 1998-12258	19980402
TR 9902401	T2	20000821	TR 1999-2401	19980402
NZ 336898	A	20011026	NZ 1998-336898	19980402
JP 2001520643	T2	20011030	JP 1998-540982	19980402
JP 3455233	B2	20031014		
TR 200101905	T2	20020621	TR 2001-200101905	19980402
TR 200202738	T2	20030321	TR 2002-200202738	19980402
JP 2003176288	A2	20030624	JP 2002-352236	19980402
EE 200300214	A	20030815	EE 2003-200300214	19980402
SG 100766	A1	20031226	SG 2001-200106590	19980402
SG 100767	A1	20031226	SG 2001-200106591	19980402
IL 131318	A1	20040831	IL 1998-131318	19980402
EP 1498418	A1	20050119	EP 2004-24998	19980402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL				
EP 1498419	A1	20050119	EP 2004-24999	19980402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL				
IL 156977	A1	20050320	IL 1998-156977	19980402
AT 292129	E	20050415	AT 1998-915281	19980402
CN 1636994	A	20050713	CN 2004-10092312	19980402
ES 2241133	T3	20051016	ES 1998-915281	19980402
NO 9905221	A	19991228	NO 1999-5221	19991026
MX 9909860	A	20000331	MX 1999-9860	19991027
US 6432994	B1	20020813	US 2000-403599	20000327
HK 1028033	A1	20050506	HK 2000-107366	20001117
US 2001039289	A1	20011108	US 2001-792237	20010223
US 6458805	B2	20021001		



AB Thienyl-, furyl- and pyrrolyl-sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides, are provided. In particular, the disclosure includes N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides, and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor. The compounds are described by the formula Ar2SO2NHAr1 [I; Ar1 = (un)substituted aryl, particularly isoxazolyl; Ar2 = biol. effective group for inhibiting endothelin binding by $\geq 50\%$ at $\leq 100 \mu\text{M}$, notably thienyl, furyl, pyrrolyl, etc.]. Methods for treating endothelin-mediated disorders by administering effective amts. of I or their prodrugs are also provided. Such disorders include hypertension, cardiovascular disease, asthma, hypertension, inflammatory disease, glaucoma, etc. Approx. 190 synthetic examples are given, and numerous example compounds were prepared, tested, and/or claimed. For instance, 5-amino-4-bromo-3-methylisoxazole was treated with NaH in THF, followed by thiophene-2-sulfonyl chloride, to give 34% title compound II. The similarly prepared title compound III had IC50 values of 0.024 μM for ETA receptors and 7.95 μM for ETB receptors, indicating substantial selectivity for ETA.

ACCESSION NUMBER: 1999:640160 HCAPLUS
 DOCUMENT NUMBER: 131:271803
 TITLE: Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
 INVENTOR(S): Chan, Ming Fai; Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy; Kois, Adam; Verner, Erik Joel; Castillo, Rosario; Silvestre; Yalamorri, Venkatachalapathi; Balaji, Vitukudi Narayanaiyengar
 PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
 SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 477,223.
 CODEN: USXXAM
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5962490	A	19991005	US 1996-721183	19960927
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
US 5591761	A	19970107	US 1994-222287	19940405
US 5571821	A	19961105	US 1994-247072	19940520
US 5594021	A	19970114	US 1995-477223	19950606

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

VO 9631492 A1 19961010 WO 1996-US4759 19960404

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LA, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN

CA 2261760 AA 19980402 CA 1997-2261760 19970926

CA 2261760 C 20050329

WO 9813366 A1 19980402 WO 1997-US17402 19970926

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LA, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9745059 A1 19980417 AU 1997-45059 19970926

AU 736269 B2 20010726

EP 946552 A1 19991006 EP 1997-943629 19970926

EP 946552 B1 20040707

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

CN 1231664 A 19991013 CN 1997-198343 19970926

BR 9711550 A 20000118 BR 1997-11550 19970926

JP 2000507607 T2 20000620 JP 1998-515979 19970926

JP 3743520 B2 20060208

NZ 334797 A 20010223 NZ 1997-334797 19970926

US 6420567 B1 20020716 US 1997-938325 19970926

JP 2002308875 A2 20021023 JP 2002-101613 19970926

EP 1342721 A1 20030910 EP 2003-7240 19970926

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL

AT 270669 B 20040715 AT 1997-943629 19970926

CN 1530366 A 20040922 CN 2003-2003158478 19970926

PT 946552 T 20041029 PT 1997-943629 19970926

ES 2224271 T3 20050301 ES 1997-943629 19970926

NO 9901388 A 19990527 NO 1999-1388 19990322

US 6331637 B1 20011218 US 1999-274280 19990322

KR 2000048681 A 20000725 KR 1999-702629 19990326

AU 9935803 A1 19990916 AU 1999-35803 19990622

AU 726595 B2 20001116

US 2002091272 A1 20020711

US 6632829 B2 20031014

US 2003208084 A1 20031106

US 2003-447763 20030528

US 1987-100865 A2 19870925

US 1990-416199 A2 19900515

US 1993-65202 B2 19930520

US 1993-100125 B2 19930730

US 1993-100565 A2 19930730

US 1993-142159 A2 19931021

US 1993-142552 A2 19931021

US 1993-142631 B2 19931021

US 1994-222287 A2 19940405

US 1994-247072 A2 19940520

US 1995-417075 A2 19950404

US 1995-477223 A2 19950606

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

WO 1996-US4759 A2 19960404

US 1995-416199 A 19950404

AU 1996-53367 A 19960404

US 1996-721183 A 19960927

EP 1997-943629 A3 19970926

JP 1998-515979 A3 19970926

US 1997-938325 A3 19970926

WO 1997-US17402 W 19970926

US 2001-11610 A3 20011105

OTHER SOURCE(S): MARPAT 131:271803


IT 184041-00-79, N-[(2-Methoxyethoxy)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-3-[(phenylamino)carbonyl]-5-(trimethylsilyl)thiophene-2-sulfonamide

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Intermediate; preparation of thienyl-, furyl- and pyrrolyl-based sulfonamides and analogs as endothelin agonists and antagonists)

RN 184041-00-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]-N-phenyl-5-(trimethylsilyl)- (9CI) (CA INDEX NAME)




IT 184035-85-6P, N-(3,4-Dimethyl-5-isoxazolyl)-3-[(phenylamino)carbonyl]thiophene-2-sulfonamide

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of thienyl-, furyl- and pyrrolyl-based sulfonamides and analogs as endothelin agonists and antagonists)

RN 184035-85-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN

ED Entered STN: 13 Nov 1998

AB R2S02N0R1 [I: R1 = bi- or tricycloalkyl, heterocyclyl, (hetero)aryl; R2 = CH:CHPh, thienyl, (iso)quinolyl, indolyl, etc.] were prepared Thus, 5-amino-4-bromo-3-methylisoxazole was amidated by thiophene-2-sulfonyl chloride to give I (R1 = 4-bromo-3-methyl-5-isoxazolyl, R2 = 2-thienyl). Data for biol. activity of I were given.

ACCESSION NUMBER: 1998:721695 HCAPLUS

DOCUMENT NUMBER: 129:343488

TITLE: Preparation of heteroaromatic sulfonamides as endothelin antagonists

INVENTOR(S): Wu, Chengde; Blok, Natalie; Kogan, Timothy; Keller, Karin; Woodard, Patricia

PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA

SOURCE: PCT Int. Appl., 205 pp.

CODEN: PTKXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9849162	A1	19981105	WO 1998-US6680	19980402
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LA, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SE, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5783705	A	19980721	US 1997-847797	19970428
US 6248767	B1	20010619	US 1997-938444	19970926
CA 2281090	AA	19981105	CA 1998-2281090	19980402
CA 2281090	C	20050607		
AU 9869504	A1	19981124	AU 1998-69504	19980402
AU 749167	B2	20020620		
EP 980369	A1	20000223	EP 1998-915281	19980402
EP 980369	B1	20050330		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 9900469	A	20000615	EE 1999-469	19980402
EE 4156	B1	20031015		
BR 9812258	A	20000725	BR 1998-12258	19980402
NZ 336898	A	20011026	NZ 1998-336898	19980402
JP 2001520643	T2	20010330	JP 1998-540982	19980402
JP 3455233	B2	20031014		
IL 131318	A1	20040831	IL 1998-131318	19980402
IL 156977	A1	20050320	IL 1998-156977	19980402
AT 292129	E	20050415	AT 1998-915281	19980402
NO 9905221	A	19991228	NO 1999-5221	19991026
MX 9909860	A	20000331	MX 1999-9860	19991027
US 6432994	B1	20020813	US 2000-403599	20000327
HK 1028033	A1	20050506	HK 2000-107366	20001117


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 129:343488

IT 184035-85-6P


RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of heteroatom sulfonamides as endothelin antagonists)
 RN 184035-85-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ED Entered STN: 15 Apr 1998
 GI




AB R1502NHR [I: R = (un)substituted (hetero)aryl; R1 = R2Z2Z1; R2 = (un)substituted Ph; Z1 = thiophene, furan, pyrrole-2,3- or -3,2-diyl, etc.; Z2 = COCH₂, CONH, CO₂, CH₂CH₂, etc.] were prepared. Thus, 2-methoxycarbonyl-3-thiophenesulfonyl chloride was amidated by 5-amino-4-chloro-3-methylisoxazole and the product converted in 5 steps to title compound II. Data for biol. activity of I were given.
 ACCESSION NUMBER: 1998:210751 HCAPLUS
 DOCUMENT NUMBER: 128:270601
 TITLE: Preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin activity modulators
 INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy P.; Blok, Natalie; Woodard, Patricia
 PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
 SOURCE: PCT Int. Appl., 172 pp.
 CODEN: P1XXD2
 LANGUAGE: Patent
 English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813366	A1	19980402	WO 1997-US17402	19970926
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ES, FI, GB, GE, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5962490	A	19991005	US 1996-721183	19960927
CA 2261760	AA	19980402	CA 1997-2261760	19970926
CA 2261760	C	20050329		
AU 9745059	A1	19980417	AU 1997-45059	19970926
AU 736269	B2	20010726		
EP 946552	A1	19991006	EP 1997-943629	19970926
EP 946552	B1	20040707		

L4 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 BR 9711550 A 20000118 BR 1997-11550 19970926
 JP 20000507607 T2 20000620 JP 1998-515979 19970926
 JP 3743520 B2 20060208
 NZ 334797 A 20010223 NZ 1997-334797 19970926
 AT 270669 S 20040715 AT 1997-943629 19970926
 WO 9901388 A 19990527 NO 1999-1388 19990322
 AU 9935803 A1 19990916 AU 1999-35803 19990622
 AU 726595 B2 20001116


PRIORITY APPLN. INFO.:
 US 1996-721183 A 19960927
 US 1987-100865 A2 19870925
 US 1990-416199 A2 19900515
 US 1993-65202 B2 19930520
 US 1993-100125 B2 19930730
 US 1993-100565 A2 19930730
 US 1993-142159 A2 19931021
 US 1993-142552 A2 19931021
 US 1993-142631 B2 19931021
 US 1994-222287 A2 19940405
 US 1994-247072 A2 19940520
 US 1995-417075 A2 19950404
 US 1995-477223 A2 19950606
 AU 1996-55367 A 19960404
 WO 1996-45759 A2 19960404
 WO 1997-US17402 W 19970926

OTHER SOURCE(S): MARPAT 128:270601
 IT 184035-85-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin activity modulators)
 RN 184035-85-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ED Entered STN: 12 Feb 1997
 GI



AB Thieryl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. The compounds include sulfonamides Ar1502NHR1 [I: Ar1 = (un)substituted (cyclo)alk(en)ynyl, aryl, heterocyclyl, bi- or tricyclyl; Ar2 = (un)substituted thieryl, furyl, pyrrolyl, benzothienyl, benzofuryl, indolyl]. In particular, N-(isoxazolyl) amides, and methods using them to inhibit binding of endothelin peptides to endothelin receptors, are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more compounds I, or prodrugs thereof, are also provided. Over 160 synthetic examples and the results of a variety of bioassays are given. For instance, amidation of thiophene-2-sulfonyl chloride with 5-amino-4-bromo-3-methylisoxazole after treatment of the latter with NaH in dry THF gave 34% of the amide II. In an endothelin receptor assay, the amide III had IC50 values of 0.0006 μM and 1.99 μM at ETA and ETB receptors, resp.

ACCESSION NUMBER: 1997:97729 HCAPLUS
 DOCUMENT NUMBER: 126:171477
 TITLE: Thieryl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
 INVENTOR(S): Chan, Ming F.; Raju, Bore G.; Kois, Adam; Verner, Erik J.; Wu, Chengde; Castillo, Rosario S.; Yalamoori, Venkatachalapathi; Balaji, Vitukudi N.
 PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
 SOURCE: U.S., 77 pp., Cont.-in-part of U.S. Ser. No. 247,072.
 CODEN: USXXAM
 LANGUAGE: Patent
 English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5594021	A	19970114	US 1995-477223	19950606
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
US 5591761	A	19970107	US 1994-222287	19940405
US 5571821	A	19961105	US 1994-247072	19940520
CA 2217169	AA	19961010	CA 1996-2217169	19960404
CA 2217169	C	20050329		
CA 2288439	AA	19961010	CA 1996-2288439	19960404
CA 2288439	C	20030401		

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

CA 2420614 AA 19961010 CA 1996-2420614 19960404
 WO 9631492 A1 19961010 WO 1996-US4759 19960404

V: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LX, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN

AU 9655367 A1 19961023 AU 1996-55367 19960404
 AU 711968 B2 19991028
 EP 819125 A1 19980121 EP 1996-912600 19960404
 EP 819125 B1 20030618

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI

CN 1184470 A 19980610 CN 1996-193973 19960404
 CN 1130355 B 20031210
 JP 11507015 T2 19990622 JP 1996-530524 19960404
 JP 3233642 B2 20011126
 NZ 306734 A 20000128 NZ 1996-306734 19960404
 NZ 500282 A 20000128 NZ 1996-500282 19960404
 EP 1048657 A1 20001102 EP 2000-113076 19960404

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI

JP 2002030075 A2 20020129 JP 2001-171692 19960404
 JP 3527217 B2 20040517
 AT 243203 E 20030715 AT 1996-912600 19960404
 PT 819125 T 20031128 PT 1996-912600 19960404
 ES 2201181 B1 20040316 ES 1996-912600 19960404
 PL 186854 B1 20040331 PL 1996-322707 19960404
 US 5962490 A 19991005 US 1996-721183 19960927
 TW 492966 B 20020701 TW 1996-85112218 19961004
 NO 9704577 A 19971204 NO 1997-4577 19971003
 NO 315607 B1 20030929
 MX 9707630 A 20000331 MX 1997-7630 19971003
 HK 1001769 A1 20040130 HK 1998-100844 19980205
 US 6331637 B1 20011218 US 1999-274280 19990322
 AU 9935803 A1 19990916 AU 1999-35803 19990622
 AU 726595 B2 20001116
 US 2002095041 A1 20020718 US 2001-6256 20011204
 US 6613804 B2 20030902
 JP 2004043495 A2 20040212 JP 2003-318261 20030910
 US 1993-65202 B2 19930520
 US 1993-100125 B2 19930730
 US 1993-100565 B2 19930730
 US 1993-142159 A2 19931021
 US 1993-142552 A2 19931021
 US 1993-142631 B2 19931021
 US 1994-222287 A2 19940405
 US 1994-247072 A2 19940520
 US 1995-417075 B2 19950404
 US 1987-100865 A2 19870925
 US 1990-416199 A2 19900515
 US 1995-416199 A 19950404
 US 1995-477223 A 19950606
 AU 1996-55367 A 19960404
 CA 1996-2217169 A3 19960404
 EP 1996-912600 A3 19960404
 JP 1996-530524 A3 19960404

PRIORITY APPLN. INFO.:


L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

JP 2001-171692 A3 19960404
 WO 1996-US4759 W 19960404
 US 1996-721183 A1 19960927
 US 1997-913331 A3 19971107

OTHER SOURCE(S): MARPAT 126:171477


IT 184041-00-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of heterocyclic sulfonamides as endothelin agonists and antagonists)

RN 184041-00-7 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)](2-methoxyethoxy)methyl]amino]sulfonyl]-N-phenyl-5-(trimethylsilyl)- (9CI) (CA INDEX NAME)



IT 184035-85-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic sulfonamides as endothelin agonists and antagonists)

RN 184035-85-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN

ED Entered STN: 06 Feb 1997

AB Thiophenyl-, furyl-, and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, isoxazolyl-thiophenyl-sulfonamides, isoxazolyl-furyl-sulfonamides and isoxazolyl-pyrrolyl-sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amts. of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

ACCESSION NUMBER: 1997:85523 HCAPLUS
 DOCUMENT NUMBER: 126166488
 TITLE: Thiophenyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

INVENTOR(S): Chan, Ming F.; Raju, Bore G.; Kois, Adam Verner, Erik J.; Wu, Chengde; Castillo, Rosario S.; Yalamoori, Venkatachalapathi; Balaji, Vitukudi N.

PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA

SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,514,691.
 CODEN: USXKAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5591761	A	19970107	US 1994-222287	19940405
US 5464853	A	19951107	US 1993-142159	19931021
US 5514691	A	19960507	US 1993-142552	19931021
CA 2161346	AA	19941208	CA 1994-2161346	19940520
CA 2161346	C	20041123		
WO 9427979	A1	19941208	WO 1994-US5755	19940520
V: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LX, LU, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9469646	A1	19941220	AU 1994-69646	19940520
AU 691813	B2	19980528		
GB 2285625	A1	19950719	GB 1995-3693	19940520
GB 2285625	B2	19971210		
EP 699191	A1	19960306	EP 1994-918081	19940520
EP 699191	B1	19981216		
R: AT, BE, CH, DE, DK, ES, FR, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5571821	A	19961105	US 1994-247072	19940520
JP 08510744	T2	19961112	JP 1995-500856	19940520
EP 870764	A1	19981014	EP 1998-109339	19940520
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 174592	E	19990115	AT 1994-918081	19940520
ES 2127397	T3	19990416	ES 1994-918081	19940520
RU 2151144	C1	20000620	RU 1995-121744	19940520
EP 1069114	A2	20010117	EP 2000-119107	19940520
EP 1069114	A3	20010131		
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 5594021	A	19970114	US 1995-477223	19950606
US 5962490	A	19991005	US 1996-721183	19960927
US 6030991	A	20000229	US 1996-730633	19961206
AU 9860585	A1	19980604	AU 1998-60585	19980331
AU 724575	B2	20000928		

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

US 6331637 B1 20011218 US 1999-274280 19990322
 AU 9935803 A1 19990916 AU 1999-35803 19990622
 AU 726595 B2 20001116
 US 2001036958 A1 20011101 US 2000-749716 20001227
 US 6541498 B2 20030401


PRIORITY APPLN. INFO.:

US 1993-65202 B2 19930520
 US 1993-100125 B2 19930730
 US 1993-100565 B2 19930730
 US 1993-142159 A2 19931021
 US 1993-142552 A2 19931021
 US 1993-142631 B2 19931021
 US 1987-100865 A2 19870925
 US 1990-416199 A2 19900515
 US 1994-222287 A 19940405
 EP 1994-918081 A3 19940520
 EP 1998-109339 A3 19940520
 US 1994-247072 A2 19940520
 WO 1994-US5755 W 19940520
 US 1995-416199 B1 19950404
 US 1995-417075 B2 19950404
 US 1995-477223 A2 19950606
 AU 1996-55367 A 19960404
 WO 1996-US4759 A2 19960404
 US 1996-721183 A1 19960927
 US 1996-730633 A1 19961206
 US 1999-439802 A1 19991112


OTHER SOURCE(S): MARPAT 126:166488

IT 187218-38-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of sulfonamides and modulation of endothelin binding to receptor and treatment of endothelin-mediated disorders)

RN 187218-38-8 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(4-bromo-3-methyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 01 Jan 1997
 GI




AB R2SO2NHR1 [R1 = (hetero)aryl; R2 = (un)substituted biphenyl, -2- or -3-furyl, -thienyl, -pyrrolyl] were prepared. Thus, 5-amino-4-bromo-3-methylisoxazole (preparation given) was amidated by thiophene-2-sulfonyl chloride to give title compound II. Data for biol. activity of I were given.

ACCESSION NUMBER: 1996:761669 HCAPLUS
 DOCUMENT NUMBER: 126:31342
 TITLE: Preparation of N-isoxazolythiophenesulfonamides and analogs as endothelin receptor antagonists
 INVENTOR(S): Chan, Ming Fai; Raju, Bore Gowda; Kois, Adam; Verner, Erik Joel; Wu, Chengde; Castillo, Rosario Silverstre; Yalamoori, Venkatachalspathi; Balaaji, Vitukudi Narayanaiyanga
 PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: FIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9631492	A1	19961010	WO 1996-US4759	19960404
US 5594021	A	19970114	US 1995-477223	19950606
AU 9655367	A1	19961023	AU 1996-55367	19960404
EP 819125	B1	19980121	EP 1996-912600	19960404
EP 819125	B1	20030618		
BR 9604875	A	19980519	BR 1996-4875	19960404
JP 11507015	T2	19990622	JP 1996-530524	19960404
JP 3223642	B2	20011126		
NZ 306734	A	20000128	NZ 1996-306734	19960404
AT 243203	Z	20030715	AT 1996-912600	19960404
PL 186854	B1	20040331	PL 1996-322707	19960404
US 5962490	A	19991005	US 1996-721183	19960927
NO 9704577	A	19971204	NO 1997-4577	19971003

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (CA INDEX NAME)




L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 315607	B1	20030929		
MX 9707630	A	20000331	MX 1997-7630	19971003
US 2001021714	A1	20010913	US 1997-913331	19971107
US 6342610	B2	20020129		
HK 1001769	A1	20040130	HK 1998-100844	19980205
US 6331637	B1	20011218	US 1999-274280	19990322
AU 9935803	A1	19990916	AU 1999-35803	19990622
AU 726595	B2	20001116		
US 2002091272	A1	20020711	US 2001-11610	20011105
US 6632829	B2	20031014		


PRIORITY APPLN. INFO.:
 US 1995-416199 A 19950404
 US 1995-417075 A 19950404
 US 1995-477223 A 19950606
 US 1987-100865 A2 19980925
 US 1990-416199 A2 19900515
 US 1993-65202 B2 19930520
 US 1993-100125 B2 19930730
 US 1993-100565 B2 19930730
 US 1993-142159 A2 19931021
 US 1993-142552 A2 19931021
 US 1993-142631 B2 19931021
 US 1994-222287 A2 19940405
 US 1994-247072 A2 19940520
 AU 1996-55367 A 19960404
 WO 1996-54759 W 19960404
 US 1996-721183 A1 19960927
 US 1997-938325 A3 19970926

OTHER SOURCE(S): MARPAT 126:31342
 IT 184035-85-6p
 RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-isoxazolythiophenesulfonamides and analogs as endothelin receptor antagonists)
 RN 184035-85-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-N-phenyl- (9CI) (CA INDEX NAME)



IT 184041-00-7p
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N-isoxazolythiophenesulfonamides and analogs as endothelin receptor antagonists)
 RN 184041-00-7 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[(3,4-dimethyl-5-isoxazolyl) [(2-methoxyethoxy)methyl]amino]sulfonyl]-N-phenyl-5-(trimethylsilyl)- (9CI)

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 20 Apr 1985
 GI




AB Blue dyes were prepared having the general formula I (R = CN, alkoxy, alkoxyalkyl, alkoxyalkyl, alkoxyalkyl, alkoxyalkyl, COR4; R1 = H, C1-4 alkyl, phenyl; R2 = NO2, CN, alkoxy, alkoxyalkyl, COR4; R3 = (un)substituted aminophenyl, aminoquinolyl, aminonaphthyl; R4 = H, C1-6 alkyl, phenyl). Thus, 2-amino-5-(2,2-dicyanovinyl)-3-nitrothiophene [95551-97-6] was diazotized and coupled with N,N-diethyl-m-toluidine [91-67-8] to give I (R = CN; R1 = H; R2 = NO2; R3 = 2,4-Me2Et2N)C6H3 [95551-98-7].

ACCESSION NUMBER: 1985:133543 HCAPLUS
 DOCUMENT NUMBER: 102:133543
 TITLE: Monoazo disperse dyes for polyester fibers
 PATENT ASSIGNEE(S): Gosei Senryo Gijutsu Kenkyu Kumiai, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
 CODEN: JKXKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59204658	A2	19841120	JP 1983-79360	19830509
JP 03016983	B4	19910306		

PRIORITY APPLN. INFO.: JP 1983-79360 19830509
 IT 95551-77-2
 RL: TDM (Technical or engineered material use); USES (Uses)
 (dye, blue, for polyester fibers)
 RN 95551-77-2 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[[[7-(acetyl amino)-1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2,2,4-trimethyl-6-quinolyl]azo]-4-butyl-5-(2-cyanoethenyl)-N-phenyl- (9CI) (CA INDEX NAME)



10781442amend

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

74.07

241.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-10.50

-10.50

SESSION WILL BE HELD FOR 60 MINUTES


STN INTERNATIONAL SESSION SUSPENDED AT 09:11:28 ON 26 JUN 2006

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak

G2 N,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:02:01 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 267 TO ITERATE

100.0% PROCESSED 267 ITERATIONS

SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 4360 TO 6320

PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:02:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5528 TO ITERATE

100.0% PROCESSED 5528 ITERATIONS

SEARCH TIME: 00.00.01

228 ANSWERS

L3 228 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
166.94	167.15

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 13:02:10 ON 26 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jun 2006 VOL 145 ISS 1
FILE LAST UPDATED: 25 Jun 2006 (20060625/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 5 L3

=> d ed abs ibib hitstr 1-5

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Mar 2005
GI



AB The invention relates to a preparation of urotensin II receptor antagonists and CCR-9 antagonists of formula I [wherein: R1, R2, and R3 are independently selected from H, halogen, alkyl, aryl, or CN, etc.; X is CH2, O, or NH, etc.; Y is SO2, C(O), CH2SO2, NHC(O), or NHSO2, etc.; T and W are independently selected from H, (cyclo)alkyl, alkoxy, aryl, or halogen, etc.; R4 is aryl, heterocyclyl, or cycloalkyl]. For instance, thiophenecarboxamide derivative II was prepared via amidation of thiophene-2-carboxylic acid by [2,4,6-trimethyl-3-(pyrrolidin-1-yl)phenyl]amine. The invention compds. were tested for inhibition of human urotensin II-induced Ca2+ mobilization in UTR cells (IC50 > 0.5 μ M).

ACCESSION NUMBER: 2005:185392 HCAPLUS
 DOCUMENT NUMBER: 142:280229
 TITLE: A preparation of urotensin II receptor antagonists and CCR-9 antagonists
 INVENTOR(S): Wu, Chengde; Anderson, C. Eric; Bui, Huong; Gao, Daxin; Kassir, Jamal; Li, Wen; Wang, Junmei; Biediger, Ronald; Chen, Jie; Market, Robert V.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 781,442.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005049286	A1	20050303	US 2004-924180	20040823
US 2004180892	A1	20040916	US 2004-781442	20040218
PRIORITY APPLN. INFO.:			US 2003-448791P	P 20030220
			US 2004-781442	A2 20040218

OTHER SOURCE(S): MARPAT 142:280229


IT 749268-37-9P 749268-38-0P 847414-20-4P
 847414-21-5P 847414-22-6P 847414-24-8P
 847414-26-0P 847414-27-1P 847414-30-6P
 847414-31-7P 847414-33-9P 847414-34-0P
 847414-35-1P 847414-36-2P 847414-37-3P
 847414-38-4P 847414-39-5P 847414-40-8P
 847414-41-9P 847414-42-0P 847414-43-1P
 847414-44-2P 847414-45-3P 847414-46-4P
 847414-47-5P 847414-48-6P 847414-49-7P
 847414-50-0P 847414-51-1P 847414-52-2P
 847414-53-3P 847414-60-2P 847414-61-3P
 847414-62-4P 847414-63-5P 847414-64-6P
 847414-65-7P 847414-67-9P 847414-70-4P
 847414-71-5P 847414-72-6P 847414-73-7P
 847414-74-8P 847414-75-9P 847414-77-1P
 847414-80-6P 847414-82-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of urotensin II receptor antagonists and CCR-9 antagonists)


RN 749268-37-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 749268-38-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-20-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 847414-21-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 847414-22-6 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(methoxymethyl)(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-24-8 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-26-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-27-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-30-6 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3-(1-pyrrolidinyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-31-7 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[2-(3-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-33-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3-(3-methoxyphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-34-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[(3-methylphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-35-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[(4-methylphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-36-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl) sulfonyl] amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-37-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl) sulfonyl] amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-38-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-39-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-40-8 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-41-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-42-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3-chlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-43-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[2-chlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-44-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-45-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-46-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-fluorophenyl) sulfonyl] amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-47-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(2-bromophenyl) sulfonyl] amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-48-6 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,5-dichlorophenyl) sulfonyl] amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-49-7 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3,5-difluorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-50-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3,4-dichlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-51-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-52-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-53-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,4,5-trifluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-60-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-[2,6-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-61-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-[2,4-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-62-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[2-fluorophenyl]amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-63-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-fluorophenyl) amino] sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-64-6 HCAPLUS


CN 2-Thiophenecarboxamide, 3-[[(3-fluorophenyl) amino] sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-65-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-bromo-2,4,6-trimethylphenyl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

RN 847414-67-9 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

RN 847414-70-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-cyclopropyl-2,4,6-trimethylphenyl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


RN 847414-71-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[[(4-
fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 847414-72-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 847414-73-7 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethyl[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 847414-74-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-75-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,2',4,6,6'-pentamethyl[1,1'-biphenyl]-3-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-77-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(diethylamino)-2,4,6-trimethylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-80-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-methoxy-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)






RN 847414-82-8 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[methyl(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 02 Sep 2004
 GI



AB The title compds. I and II [R1, R2, R3 = H, halo, alkyl, aryl, aralkyl, CN, CF3, etc.; X = N, CH2, or O; Y = SO2, CO, CH2SO2, CH2CO, NHCO, OCO, or NHSO2; R4 = alkyl, aralkyl or (hetero)aryl, R5 = R1, or Z-NR7R8, or R4, R5 taken together with N can form a 5 or 6 membered ring; Z = (CH2)_n, where n = 0-6; R6 = (hetero)aryl, Z-NR7R8; R7, R8 = H, alkyl, aryl, aralkyl or together with N form a pyrrolidine, piperazine, piperidine, or morpholine ring; E = substituted amino, O, S, CR13=CR14, or CR13=N, where R13, R14 = alkyl, (hetero)aryl, halo, OH, alkoxy, etc.; D = substituted amino, O, or S; Z = NR15 or CR15R15 where each R15 = H, alkyl, aryl, or heteroaryl; A = (substituted)amino, CO, or SO2; when A = (substituted)amino, B = SO2, CO2, or Cl6R16, where R16 = H, alkyl, aryl, or heteroaryl; when A = CO or SO2, B = (substituted)amino; R9, R10 = H, alkyl, (hetero)aryl, halo, OH, Alkoxy, or (substituted)amino; R11, R12 = H, alkyl, or (hetero)aryl] were prepared as urotensin-II receptor antagonists and CCR-9 antagonists for the treatment of congestive heart failure, stroke, ischemic heart disease, etc. For example, reaction of 2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylamine (preparation given) with 1-naphthalenesulfonyl chloride yielded compound III. The latter showed an IC50 = 10 μ M in the assay of human urotensin-II-induced CA2+ mobilization in UTR cells.

ACCESSION NUMBER: 2004:718308 HCAPLUS
 DOCUMENT NUMBER: 141:243188
 TITLE: Preparation of phenylenediamine and thiophene carboxylic amide derivatives as urotensin-II receptor antagonists and CCR-9 antagonists
 INVENTOR(S): Wu, Chengde; Anderson, Eric C.; Bui, Huong; Gao, Daxin; Kassir, Jamal; Li, Wen; Wang, Junmei; Market, Robert V.
 PATENT ASSIGNEE(S): Encysive Pharmaceuticals Inc., USA
 SOURCE: PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073634	A2	20040902	WO 2004-US4645	20040218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004212985	A1	20040902	AU 2004-212985	20040218
CA 2515780	AA	20040902	CA 2004-2515780	20040218
EP 1610753	A2	20060104	EP 2004-712313	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2003-448791P	P 20030220
			WO 2004-US4645	W 20040218
OTHER SOURCE(S): MARPAT 141:243188				
IT 749268-37-9P , 3-Phenylaminosulfonyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide 749268-38-0P , 3-Benzenesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of phenylenediamine and thiophene carboxylic amide derivs. as urotensin-II receptor antagonists and CCR-9 antagonists)


RN 749268-37-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




IT 749268-61-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)




(Preparation of phenylenediamine and thiophene carboxylic amide derivs. as urotensin-II receptor antagonists and CCR-9 antagonists)

RN 749268-61-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(methoxymethyl)phenylamino]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 12 Apr 2002
 GI



AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

ACCESSION NUMBER: 2002:275753 HCAPLUS
 DOCUMENT NUMBER: 136:309843
 TITLE: Preparation of thiophenes as phosphate transport inhibitors
 INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028353	A2	20020411	WO 2001-US31318	20011005
WO 2002028353	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,

US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002013048 A5 20020415 AU 2002-13048 20011005
 PRIORITY APPLN. INFO.: US 2000-238068P P 20001005
 WO 2001-US31318 W 20011005

OTHER SOURCE(S): MARPAT 136:309843

IT 409361-91-7P 409361-92-8P 409361-93-9P
 409361-94-0P 409361-99-5P 409362-00-1P
 409362-01-2P 409362-02-3P 409362-03-4P
 409362-04-5P 409362-05-6P 409362-06-7P
 409362-11-4P 409362-12-5P 409362-13-6P
 409362-14-7P 409362-17-0P 409362-18-1P
 409362-19-2P 409362-20-5P 409362-22-7P
 409362-28-3P 409362-29-4P 409362-30-7P
 409362-31-8P 409362-32-9P 409362-33-0P
 409362-34-1P 409362-35-2P 409362-36-3P
 409362-37-4P 409362-38-5P 409362-39-6P
 409362-40-9P 409362-41-0P 409362-42-1P
 409362-43-2P 409362-44-3P 409362-45-4P
 409362-46-5P 409362-47-6P 409362-48-7P
 409362-49-8P 409362-50-1P 409362-51-2P
 409362-52-3P 409362-53-4P 409362-54-5P
 409362-55-6P 409362-56-7P 409362-57-8P
 409362-58-9P 409362-59-0P 409362-60-3P
 409362-61-4P 409362-62-5P 409362-63-6P
 409362-64-7P 409362-65-8P 409362-66-9P
 409362-67-0P 409362-68-1P 409362-69-2P
 409362-70-5P 409362-71-6P 409362-72-7P
 409362-73-8P 409362-75-0P 409362-76-1P
 409362-77-2P 409362-78-3P 409362-81-8P
 409362-82-9P 409362-83-0P 409362-84-1P
 409362-85-2P 409362-87-4P 409362-93-2P
 409362-95-4P 409362-97-6P 409362-98-7P
 409363-00-4P 409363-01-5P 409363-02-6P
 409363-03-7P 409363-04-8P 409363-05-9P
 409363-06-0P 409363-07-1P 409363-08-2P
 409363-10-6P 409363-15-1P 409363-17-3P
 409363-19-5P 409363-21-9P 409363-25-3P
 409363-27-5P 409363-28-6P 409363-29-7P
 409363-30-0P 409363-31-1P 409363-32-2P
 409363-35-5P 409363-36-6P 409363-41-3P
 409363-51-5P 409363-52-6P 409363-53-7P
 409363-54-8P 409363-57-1P 409363-58-2P
 409363-59-3P 409363-60-6P 409363-61-7P
 409363-62-8P 409363-63-9P 409363-64-0P
 409363-65-1P 409363-66-2P 409363-67-3P
 409363-69-5P 409363-70-8P 409363-71-9P
 409363-72-0P 409363-73-1P 409363-74-2P
 409363-75-3P 409363-76-4P 409363-77-5P
 409363-78-6P 409363-79-7P 409363-80-0P
 409363-81-1P 409363-82-2P 409363-83-3P
 409363-84-4P 409363-85-5P 409363-86-6P
 409363-87-7P 409363-88-8P 409363-89-9P
 409363-90-2P 409363-91-3P 409363-92-4P
 409363-93-5P 409363-94-6P 409363-95-7P
 409363-96-8P 409363-97-9P 409363-98-0P
 409363-99-1P 409364-00-7P 409364-01-8P
 409364-02-9P 409364-03-0P 409364-04-1P


409364-05-2P 409364-06-3P 409364-29-0P
 409364-31-4P 409364-33-6P 409364-35-8P
 409364-37-0P 409364-39-2P 409364-41-6P
 409364-43-8P 409364-45-0P 409364-47-2P
 409364-49-4P 409364-51-8P 409364-53-0P
 409364-54-1P 409364-56-3P 409364-64-3P
 409364-65-4P 409364-66-5P 409364-81-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiophenes as phosphate transport inhibitors)


RN 409361-91-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409361-92-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[2-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409361-93-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[4-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409361-94-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)


RN 409361-99-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-00-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-01-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[2-(trifluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-02-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[2-(trifluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-03-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-04-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-05-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-06-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)


RN 409362-11-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-12-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[[2-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-13-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-14-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-17-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(trifluoromethyl)phenyl]-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-18-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[2-(trifluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-19-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[4-methoxyphenyl)sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 409362-20-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl) sulfonyl] amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-22-7 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl) amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-28-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[(phenylsulfonyl) amino]- (9CI) (CA INDEX NAME)




RN 409362-29-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(1-methylethyl)phenyl]-3-[(phenylsulfonyl) amino]- (9CI) (CA INDEX NAME)




RN 409362-30-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-phenoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-31-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(hexyloxy)phenyl]-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-32-9 HCAPLUS


CN 2-Thiophenecarboxamide, N-(4-methoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-33-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(1-methylethoxy)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-34-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-acetylphenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409362-35-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-benzoylphenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409362-36-3 HCAPLUS

CN Benzeneacetic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 409362-37-4 HCAPLUS

CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)




RN 409362-38-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(1-oxopropyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-39-6 HCAPLUS

CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 409362-40-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(2-hydroxyethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-41-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-42-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(diethylamino)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


RN 409362-43-2 HCAPLUS

CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 409362-44-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 409362-45-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-[(1H-indazol-6-ylamino)sulfonyl]phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-46-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 409362-47-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(hydroxymethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-48-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-cyclohexylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-49-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-50-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-51-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-52-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-phenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-53-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 409362-54-5 HCAPLUS

CN Benzoic acid, 2-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 409362-55-6 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-56-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,6-difluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-57-8 HCAPLUS

CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
methyl ester (9CI) (CA INDEX NAME)




RN 409362-58-9 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-59-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-1,3-benzodioxol-5-yl-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)

RN 409362-60-3 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)

RN 409362-61-4 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)

RN 409362-62-5 HCAPLUS


CN 2-Thiophenecarboxamide, N-(2-benzoyl-4-chlorophenyl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-63-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(1H-indol-2-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-64-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-5-isoquinolinyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-65-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-2-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-66-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-9H-fluoren-2-yl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)


RN 409362-67-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-[(phenylamino)carbonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-68-1 HCAPLUS


CN 2-Thiophenecarboxamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-69-2 HCAPLUS


CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-2-yl-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)

RN 409362-70-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-fluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)


RN 409362-71-6 HCAPLUS

CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 409362-72-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-73-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-75-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409362-76-1 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-acetylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-77-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)

RN 409362-78-3 HCAPLUS


CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-6-quinolinyl- (9CI)
(CA INDEX NAME)

RN 409362-81-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(phenylmethoxy)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


RN 409362-82-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-1-
naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409362-83-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,5-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-84-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(1H-pyrrol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-85-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-1H-indazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)




RN 409362-87-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2-fluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-93-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-ethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)




RN 409362-95-4 HCAPLUS


CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-97-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dimethylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)

RN 409362-98-7 HCAPLUS


CN 2-Thiophenecarboxamide, N-(2,3-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)

RN 409363-00-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


RN 409363-01-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-1H-benzotriazol-5-yl-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409363-02-6 HCAPLUS

CN Benzoic acid, 2-methoxy-5-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409363-03-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2-methyl-6-benzothiazolyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-04-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(1,3-dihydro-5-isobenzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-05-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-06-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(2-methyl-4-pyrimidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-07-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(5-oxazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-08-2 HCAPLUS


CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-5-quinolinyl- (9CI) (CA INDEX NAME)




RN 409363-10-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(2-chlorophenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409363-15-1 HCAPLUS
 CN Benzoic acid, 4-methoxy-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409363-17-3 HCAPLUS
 CN Benzoic acid, 4-methyl-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409363-19-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(phenylamino)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-21-9 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-8-quinolinyl- (9CI)
 (CA INDEX NAME)




RN 409363-25-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-
 trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 409363-27-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1H-inden-5-yl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

RN 409363-28-6 HCAPLUS


CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

RN 409363-29-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-1H-indol-5-yl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)


RN 409363-30-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(dimethylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-31-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-32-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2-methylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-35-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 409363-36-6 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409363-41-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,5-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-51-5 HCAPLUS


CN 2-Thiophenecarboxamide, N-[2-(phenylmethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-52-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-3-yl-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)


RN 409363-53-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(4-chlorophenoxy)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

RN 409363-54-8 HCAPLUS


CN 2-Thiophenecarboxamide, N-[2-(methylthio)phenyl]-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)

RN 409363-57-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-1-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)


RN 409363-58-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[[2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-59-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-60-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-5-benzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-61-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2-chloro-3-methylphenyl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-62-8 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-8-
oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409363-63-9 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[3-
(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-64-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-65-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[2-(3-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-66-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-(4-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-67-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-69-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-70-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-71-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-72-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[3,4-difluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-73-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[4-chloro-3,5-dimethylphenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-74-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[4-bromophenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-75-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-76-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-77-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-78-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(5-fluoro-2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-79-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-80-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[3-chloro-2-methylphenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-81-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,4-dichlorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-82-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-83-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(2-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-84-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(2-bromophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-85-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,6-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-86-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-iodophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-87-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-88-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-89-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[4-acetylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-90-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[(2-chloro-4-cyanophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-91-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[(4-cyanophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-92-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-93-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,5-dichloro-4-hydroxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-94-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,5-dimethoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-95-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-96-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-methoxy-5-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-97-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluoro-4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-98-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-99-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,5-dimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-00-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(1-methylethyl)phenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-01-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-02-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-ethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-03-0 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,4,6-trimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-04-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(2-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409364-05-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(1-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409364-06-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-29-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl) sulfonyl] amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 409364-31-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl) sulfonyl] amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 409364-33-6 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[3-(3,4-difluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-35-8 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[3-(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-37-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[[3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-39-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[3,4-difluorophenyl)sulfonyl]amino]-N-[4-(hexyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-41-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[[3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-43-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-45-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-47-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[3,4-difluorophenyl)sulfonyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-49-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-51-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-53-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[3,4-difluorophenyl]sulfonyl]amino]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 409364-54-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[[3,4-difluorophenyl]sulfonyl]amino]-
(9CI) (CA INDEX NAME)




RN 409364-56-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-64-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-5-(4-fluorophenyl)-3-[[[2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-65-4 HCAPLUS

CN [2,2'-Bithiophene]-5-carboxamide, N-(3-chlorophenyl)-4-[[2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-66-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-chlorophenyl)sulfonyl]amino]-4-methyl- (9CI) (CA INDEX NAME)




RN 409364-81-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-4-methyl-3-[[phenylsulfonyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 23 Jan 2000
 GI




AB The title compds. [I; A1 = (un)substituted phenylene, naphthylene, heteroarylene; ring A2 comprises the carbon atoms which carry the groups C(:X)NH and NHSO₂R₂ is a benzene, naphthalene, (un)saturated 3-7 membered carbocycle, etc.; R₁ = (un)substituted aryl, heterocyclyl, C1-18 alkyl; R₂ = (un)substituted aryl, heterocyclyl, C1-10 alkyl, etc.; R₃ = H, halo, CF₃, etc.; n = 0-2; X = O, NH], useful for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis, were prepared. The compds. I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. Thus, reacting 4-[[2-(4-chlorophenylsulfonyl)-4,5-dimethoxybenzoyl]amino]benzenesulfonyl fluoride (preparation given) with thiomorpholine afforded 65% II which showed 34.8-fold stimulation ([cGMP]test substance/[cGMP]control) at 50 μ M.

ACCESSION NUMBER: 2000:53572 HCAPLUS
 DOCUMENT NUMBER: 132:93104
 TITLE: Preparation of sulfur substituted
 sulfonylaminocarboxylic acid N-arylamides as
 modulators of cyclic guanosine monophosphate (cGMP)
 production
 INVENTOR(S): Schindler, Ursula; Schonafinger, Karl; Strobel,
 Hartmut
 PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2000002851	A1	20000120	WO 1999-EP4426	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19830430	A1	20000113	DE 1998-19830430	19980708
DE 19903126	A1	20000803	DE 1999-19903126	19990127
CA 2336807	AA	20000120	CA 1999-2336807	19990625
AU 9946160	A1	20000201	AU 1999-46160	19990625
AU 761983	B2	20030612		
BR 9911914	A	20010327	BR 1999-11914	19990625
EP 1095016	A1	20010502	EP 1999-929318	19990625
EP 1095016	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002520309	T2	20020709	JP 2000-559082	19990625
JP 3786579	B2	20060614		
RU 2234497	C2	20040820	RU 2001-103645	19990625
AT 309206	E	20051115	AT 1999-929318	19990625
NO 2001000013	A	20010301	NO 2001-13	20010102
PRIORITY APPLN. INFO.:			DE 1998-19830430	A 19980708
			DE 1999-19903126	A 19990127
			WO 1999-EP4426	W 19990625
OTHER SOURCE(S): MARPAT 132:93104				
IT 254877-23-1P 254877-27-5P 254878-40-5P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production)				
RN	254877-23-1 HCAPLUS			
CN	2-Thiophenecarboxamide, 3-[[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)			




RN 254877-27-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-

thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254878-40-5 HCAPLUS

CN Benzenesulfonyl fluoride, 4-[[[3-[[[4-chlorophenyl]sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 13 Jan 2000

GI



AB Title compds. [I; A1 = (substituted) phenylene, naphthylene, heteroarylene; A2 = atoms to form Ph, naphthyl, carbocyclyl, heterocyclyl rings; R1 = (substituted) aryl, heterocyclyl, alkyl; R2 = R1, amino; R3 = ≥ 1 of H, halo, CF₃, OH, alkoxy, alkoxyalkoxy, aryloxy, NO₂, cyano, amino, CO₂H, etc.; X = O, NH, etc.; n = 0-2], were prepared Thus, 4-[[2-(4-chlorophenylsulfonylamino)-4,5-dimethoxybenzoyl]amino]benzenesulfonyl fluoride was heated in thiomorpholine at 90° for 30 min. to give 65% 2-(4-chlorophenylsulfonylamino)-4,5-dimethoxy-N-[4-(thiomorpholin-4-sulfonyl)phenyl]benzamide. The latter at 50 μ M gave 34.8-fold stimulation of soluble guanylate cyclase.

ACCESSION NUMBER: 2000:31524 HCAPLUS
 DOCUMENT NUMBER: 132:93102
 TITLE: Preparation of arylsulfonylaminoarylamides as guanylate cyclase activators.
 INVENTOR(S): Schindler, Ursula; Schoenafinger, Karl; Strobel, Hartmut
 PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
 SOURCE: Ger. Offen., 24 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19830430	A1	20000113	DE 1998-19830430	19980708
CA 2336807	AA	20000120	CA 1999-2336807	19990625
WO 2000002851	A1	20000120	WO 1999-EP4426	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9946160	A1	20000201	AU 1999-46160	19990625
AU 761983	B2	20030612		
BR 9911914	A	20010327	BR 1999-11914	19990625
EP 1095016	A1	20010502	EP 1999-929318	19990625
EP 1095016	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
TR 200100147	T2	20010521	TR 2001-200100147	19990625
JP 2002520309	T2	20020709	JP 2000-559082	19990625
JP 3786579	B2	20060614		
RU 2234497	C2	20040820	RU 2001-103645	19990625
AT 309206	E	20051115	AT 1999-929318	19990625
EP 1614678	A2	20060111	EP 2005-21577	19990625
EP 1614678	A3	20060322		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY

ES 2251200	T3	20060416	ES 1999-929318	19990625
US 6335334	B1	20020101	US 1999-349933	19990708
ZA 2000007486	A	20020104	ZA 2000-7486	20001214
NO 2001000013	A	20010301	NO 2001-13	20010102
US 2002061887	A1	20020523	US 2001-994730	20011128
US 6881735	B2	20050419		
US 2004186145	A1	20040923	US 2004-816143	20040402
JP 2006143737	A2	20060608	JP 2005-343295	20051129

PRIORITY APPLN. INFO.:

DE 1998-19830430	A	19980708
DE 1999-19903126	A	19990127
EP 1999-929318	A3	19990625
JP 2000-559082	A3	19990625
WO 1999-EP4426	W	19990625
US 1999-349933	A3	19990708
US 2001-994730	A3	20011128


OTHER SOURCE(S): MARPAT 132:93102

IT **254877-23-1P 254877-27-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylaminoarylamides as guanylate cyclase activators)


RN 254877-23-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254877-27-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[4-chlorophenyl)sulfonyl]amino]-N-[4-(4-thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




IT 254878-40-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylsulfonylaminoarylamides as guanylate cyclase activators)

RN 254878-40-5 HCAPLUS

CN Benzenesulfonyl fluoride, 4-[[[3-[[[4-chlorophenyl)sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

28.08

195.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.75

-3.75

STN INTERNATIONAL LOGOFF AT 13:02:31 ON 26 JUN 2006

